Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation

Chemoimmunotherapy is the first-line standard treatment for patients with non-small cell lung cancer (NSCLC). However, there are few reports on the efficacy of chemoimmunotherapy in patients with NSCLC who harbor the MET exon 14 skipping mutation. We report the case of an 81-year-old male patient wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nitta, Naohiro, Morimoto, Yoshie, Tani, Nozomi, Shimamoto, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058577/
https://www.ncbi.nlm.nih.gov/pubmed/37007311
http://dx.doi.org/10.7759/cureus.35545
_version_ 1785016664972066816
author Nitta, Naohiro
Morimoto, Yoshie
Tani, Nozomi
Shimamoto, Takayuki
author_facet Nitta, Naohiro
Morimoto, Yoshie
Tani, Nozomi
Shimamoto, Takayuki
author_sort Nitta, Naohiro
collection PubMed
description Chemoimmunotherapy is the first-line standard treatment for patients with non-small cell lung cancer (NSCLC). However, there are few reports on the efficacy of chemoimmunotherapy in patients with NSCLC who harbor the MET exon 14 skipping mutation. We report the case of an 81-year-old male patient with lung adenocarcinoma with a MET exon 14 skipping mutation who was treated with chemoimmunotherapy and achieved a durable response. Chemoimmunotherapy may be a promising treatment option for patients with a MET exon 14 skipping mutation. However, further studies are needed to characterize the objective response rate and response duration in these populations.
format Online
Article
Text
id pubmed-10058577
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-100585772023-03-30 Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation Nitta, Naohiro Morimoto, Yoshie Tani, Nozomi Shimamoto, Takayuki Cureus Internal Medicine Chemoimmunotherapy is the first-line standard treatment for patients with non-small cell lung cancer (NSCLC). However, there are few reports on the efficacy of chemoimmunotherapy in patients with NSCLC who harbor the MET exon 14 skipping mutation. We report the case of an 81-year-old male patient with lung adenocarcinoma with a MET exon 14 skipping mutation who was treated with chemoimmunotherapy and achieved a durable response. Chemoimmunotherapy may be a promising treatment option for patients with a MET exon 14 skipping mutation. However, further studies are needed to characterize the objective response rate and response duration in these populations. Cureus 2023-02-27 /pmc/articles/PMC10058577/ /pubmed/37007311 http://dx.doi.org/10.7759/cureus.35545 Text en Copyright © 2023, Nitta et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Nitta, Naohiro
Morimoto, Yoshie
Tani, Nozomi
Shimamoto, Takayuki
Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation
title Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation
title_full Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation
title_fullStr Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation
title_full_unstemmed Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation
title_short Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation
title_sort durable response to chemoimmunotherapy of a lung adenocarcinoma harboring a met exon 14 skipping mutation
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058577/
https://www.ncbi.nlm.nih.gov/pubmed/37007311
http://dx.doi.org/10.7759/cureus.35545
work_keys_str_mv AT nittanaohiro durableresponsetochemoimmunotherapyofalungadenocarcinomaharboringametexon14skippingmutation
AT morimotoyoshie durableresponsetochemoimmunotherapyofalungadenocarcinomaharboringametexon14skippingmutation
AT taninozomi durableresponsetochemoimmunotherapyofalungadenocarcinomaharboringametexon14skippingmutation
AT shimamototakayuki durableresponsetochemoimmunotherapyofalungadenocarcinomaharboringametexon14skippingmutation

Ejemplares similares